Excelsior Biopharma Inc

Excelsior Biopharma Inc

TTPEX:6496
22.05
TWD
-1.35
(-5.77%)
-3.99EPS
1.10BMarket Cap

Total Valuation

TWD

As of September 30, 2026, Excelsior Biopharma Inc carries a market capitalization of 1.10B, placing it among publicly traded companies globally. Its enterprise value stands at 1.54B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.10B
Enterprise Value1.54B

Share Statistics

As of September 30, 2026, Excelsior Biopharma Inc has 46.58M shares outstanding.

Shares Outstanding46.58M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 1.14, and the price-to-book ratio stands at 1.67.

PS Ratio1.14
PB Ratio1.67
P/TBV Ratio1.67
P/FCF Ratio-10.79
P/OCF Ratio-11.75

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 1.61 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.54B versus a market cap of 1.10B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.61

Financial Position

As of September 30, 2026, Excelsior Biopharma Inc maintains a current ratio of 1.46, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 84.76, indicating elevated leverage, while an interest coverage ratio of -11.04 demonstrates limited ability to service its debt obligations.

Current Ratio1.46
Quick Ratio0.25
Debt / Equity84.76
Debt / EBITDA-5.08
Interest Coverage-11.04

Financial Efficiency

TWD

These figures cover the twelve months ended September 30, 2026. The company generates approximately 8.49M in revenue per employee across its workforce of 113.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee8.49M
Employee Count113.00

Taxes

TWD

Over the twelve months ended September 30, 2026, Excelsior Biopharma Inc recorded 12.06M in income tax expense. The company reported a pretax loss of -172.64M and -184.70M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax12.06M

Stock Price Statistics

TWD

As of the close on November 17, 2026, Excelsior Biopharma Inc's stock has declined approximately 24.36% over the past 52 weeks. The 50-day moving average sits at 23.88, while the 200-day moving average is 25.33.

52-Week Price Change-24.36%
50-Day Moving Average23.88
200-Day Moving Average25.33

Income Statement

TWD

Over the twelve months ended September 30, 2026, Excelsior Biopharma Inc generated 959.88M in revenue and converted that into -184.70M in net income, yielding earnings per share of -3.99. EBITDA reached -109.66M, while operating income came in at -175.44M.

Revenue959.88M
Gross Profit366.73M
Operating Income-175.44M
Pretax Income-172.64M
Net Income-184.70M
EBITDA-109.66M
EBIT-179.24M
Earnings Per Share (EPS)-3.99

Balance Sheet

TWD

As of September 30, 2026, Excelsior Biopharma Inc holds 117.87M in cash and equivalents against 557.51M in total debt, resulting in a net debt position of 214.48M. Total book value stands at 657.75M, with working capital of 216.57M providing operational flexibility.

Cash & Cash Equivalents117.87M
Total Debt557.51M
Net Debt214.48M
Equity (Book Value)657.75M
Book Value Per Share14.12
Working Capital216.57M

Cash Flow

TWD

Excelsior Biopharma Inc produced -93.15M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -8.29M in capital expenditures, free cash flow totaled -101.44M - equivalent to -2.19 per share.

Operating Cash Flow-93.15M
Capital Expenditures-8.29M
Free Cash Flow-101.44M
FCF Per Share-2.19

Margins

Over the twelve months ended September 30, 2026, Excelsior Biopharma Inc posted a gross margin of 38.21, reflecting its pricing power and cost economics. The operating margin of -18.28 and net profit margin of -19.24 provide insight into operational efficiency.

Gross Margin38.21
Operating Margin-18.28
Pretax Margin-17.99
Profit Margin-19.24
EBITDA Margin-11.42

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -9.27: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.44, meaning Excelsior Biopharma Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-13.44
FCF Yield-9.27

Scores

As of September 30, 2026, Excelsior Biopharma Inc has an Altman Z-Score of 1.08, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.08